Feasibility analysis for the monitoring of COVID-19 vaccines (ACCESS)
For more information on this project, please contact the EU PE&PV research network at eupepv@uu.nl.
Project information
- EU PE&PV research network
- EUPAS37273
- EUPAS39370
- EUPAS39361
- EUPAS39289
- Specific Contract 03 implementing Framework service contract EMA/2018/28/PE
Full title
Feasibility analysis for the monitoring of COVID-19 vaccines (ACCESS)
Principal investigator
Prof. Dr. Miriam Sturkenboom, University Medical Center Utrecht
Participating organisations
- Utrecht University, The Netherlands - consortium lead
- UMC Utrecht, The Netherlands - coordinator
- VAC4EU, Belgium
- Aarhus University, Denmark
- BIPS, Germany
- Université de Bordeaux, France
- ARS, Italy
- SoSe Te - Pedianet, Italy
- University of Messina, Italy
- Lareb, The Netherlands
- PHARMO Institute, The Netherlands
- University of Oslo, Norway
- AEMPS, Spain
- FICF, Spain
- FISABIO, Spain
- IDIAPJGol, Spain
- RTI Health Solutions, Spain
Status
Completed (2021)
Deliverables
Peer-reviewed scientific publications
Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study. Willame C, Dodd C, Durán CE, Elbers R, Gini R, Bartolini C, Paoletti O, Wang L, Ehrenstein V, Kahlert J, Haug U, Schink T, Diez-Domingo J, Mira-Iglesias A, Carreras JJ, Vergara-Hernández C, Giaquinto C, Barbieri E, Stona L, Huerta C, Martín-Pérez M, García-Poza P, de Burgos A, Martínez-González M, Bryant V, Villalobos F, Pallejà-Millán M, Aragón M, Carreras JJ, Souverein P, Thurin NH, Weibel D, Klungel OH, Sturkenboom M. Vaccine. 2023 Jan 4;41(1):251-262. doi: 10.1016/j.vaccine.2022.11.031. Epub 2022 Nov 22. PMID: 36446653; PMCID: PMC9678835.